Compare PAY & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAY | AAPG |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2021 | N/A |
| Metric | PAY | AAPG |
|---|---|---|
| Price | $24.33 | $22.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $36.29 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 731.3K | 1.6K |
| Earning Date | 05-04-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.57 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,196,507,000.00 | N/A |
| Revenue This Year | $18.85 | N/A |
| Revenue Next Year | $19.41 | $368.64 |
| P/E Ratio | $47.88 | ★ N/A |
| Revenue Growth | ★ 37.25 | N/A |
| 52 Week Low | $22.02 | $17.56 |
| 52 Week High | $40.43 | $48.45 |
| Indicator | PAY | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 37.58 |
| Support Level | $23.82 | $21.20 |
| Resistance Level | $26.18 | $25.47 |
| Average True Range (ATR) | 1.03 | 0.74 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 26.91 | 20.44 |
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.